We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioMérieux’s BIOFIRE Respiratory Panel 2.1 Plus with SARS-CoV-2 Receives CE Mark

By LabMedica International staff writers
Posted on 16 Jul 2020
Print article
Illustration
Illustration
BioMérieux’s (Marcy-l'Étoile, France) BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) is CE marked and will be commercially available in all countries that recognize CE marking.

The BIOFIRE RP2.1plus Panel is part of BioMérieux’s suite of products in response to the COVID-19 pandemic. The ARGENE SARS-CoV-2 R-GENE was launched in March 2020, followed by the US FDA EUA cleared BIOFIRE RP2.1 panel and the VIDAS anti-SARS- CoV-2 IgM and anti-SARS-CoV-2 IgG tests. The BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) tests for 23 pathogens (19 viruses, including SARS-CoV-2, and four bacteria) which are responsible for the most frequent respiratory tract infections. The new panel advances the existing BIOFIRE Respiratory Panel 2 plus (RP2plus) by adding SARS-CoV-2 to the panel menu while maintaining an assay runtime of about 45 minutes. It also includes an assay for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) allows healthcare providers to quickly identify patients with common respiratory pathogens and differentiate those with COVID-19, using one single test. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE FILMARRAY TORCH systems and is extremely easy to use.

“The availability of BIOFIRE RP2.1plus in all countries recognizing CE marking represents a global syndromic response to this unprecedented COVID-19 pandemic,” said Pierre Boulud, Chief Operating Officer, Executive Vice President, Clinical Operations at BioMérieux. “With increasing reagent production capacity and an installed base of more than 14 000 BIOFIRE units throughout the world, BIOFIRE RP2.1plus will play a key role now and in the upcoming respiratory season as healthcare providers face the regular group of respiratory pathogens as well as SARS-CoV-2.”

Related Links:
BioMérieux

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics